2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one,
LY 303511,
LY-303511,
LY303511,
LY 303511,
154447-38-8,
ly-303511,
LY303511,
8-phenyl-2-(piperazin-1-yl)-4h-chromen-4-one,
2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one,
8-phenyl-2-piperazin-1-ylchromen-4-one,
8-Phenyl-2-Piperazin-1-Yl-Chromen-4-One,
CHEMBL1363184,
2-(1-Piperazinyl)-8-phenyl-4H-1-benzopyran-4-one,
4H-1-Benzopyran-4-one,8-phenyl-2-(1-piperazinyl)-,
2-(4-Piperazinyl)-8-phenyl-4H-1-benzopyran-4-one,
AC1L1H4H,
AC1Q6AL7,
SCHEMBL619297,
8-Phenyl-2-(1-piperazinyl)-4H-1-benzopyran-4-one,
GTPL6005,
CHEBI:92399,
CTK4C8256,
DTXSID90165632,
HMS3229G19,
HMS3269C09,
HMS3677M04,
BCP08239,
EX-A1746,
ZINC2507616,
3793AH,
BDBM50210161,
IN1267,
NSC736787,
AKOS024457087,
CCG-206767,
CS-1384,
NSC-736787,
NCGC00161407-01,
NCGC00161407-02,
NCGC00161407-03,
AN-17027,
BC600526,
HY-15643,
RT-013611,
FT-0755982,
W-5304,
J-009102,
BRD-K22385716-001-01-7,
4H-1-Benzopyran-4-one, 8-phenyl-2-(1-piperazinyl)-,
8DQ,
EM-100 series,
D09VHS,
LY-3,
CID3971,
C19H18N2O2,
AR-1H4855,
EM-101,
C19-H28-N2-O2,
MTOR pathway inhibitors (cancer), NIH,
MTOR pathway inhibitors (cancer), Emiliem,
A15147,
C093555,
15687-18-0,